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epatic involvement in systemic 
disorders is common with variable 
features from fulminant liver failure to 
cholestatic, hepatocellular or mixed pictures. 
Thyroid disorders are known to be 
associated with abnormal liver enzymes1.  
Autoimmune thyroid disorders like 
hashimoto's thyroditis  and  Grave’s  disease  
may   be    associated    with     autoimmune  




diseases. reatment of hyperthyroidism with 
oral medication or radioactive iodine I131 
may cause toxic liver injury2,3,4.  
Hyperthyroidism associated cholestasis was 
reported with both severe and mild 
hyperthyroidism.  This form of cholestasis 
usually resolves after treatment of 
hyperthyroidism5, 6. This case report is a 
description of rare association of 





Thyroid disorders especially thyrotoxicosis are commonly associated with hepatic 
dysfunction but cholestasis is rarely reported.  We reported a 31-year lady with 
thyrotoxicosis- associated steatosis and cholestasis, the serological and the immunological 
markers were negative for chronic viral hepatitis and autoimmune liver diseases.  She had 
significant improvement of the liver enzymes after treatment with radio active I 131. Over 
three years follow up, the liver enzymes were fluctuating with the changes in the thyroid 
status. In conclusion re-evaluation of the liver enzymes after treatment of thyrotoxicosis will 
differentiate patients with thyrotoxicosis induced hepatic dysfunction from those with 
underlying liver disease  
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Thirty one year old lady diagnosed to have 
Grave's disease in 2001 based on clinical 
evidence of thyrotoxicosis, elevated thyroid 
function tests Thyroid stimulating (TSH) 
0.005uiU/l, Free T4 hormone( T4) 
67pmol/L, Free T3  (FT3)17pmol/L and 
positive thyroid antibodies she was treated 
with neomercazole but she was not 
compliant to the treatment and follow up.  
On March 2003 she presented to the out 
patients department with 2-year history of 
neck swelling, weight loss, heat intolerance, 
shortness of breath, dysphagia and 
secondary amenorrhea. There was no 
history of jaundice, no past or family history 
of liver disease and no history of blood 
transfusion.  She was not receiving 
hepatotoxic medication or herbal medicine 
and she was off neomerccazole for more 
than one year. On physical examination, her 
weight 56.2Kg and height 134 cm, body 
mass index 31.18, blood pressure 118/70 
mmHg, normal pulse rate with adequate 
volume and regular.  She had 
exophthalamous, positive lid retraction and 
lid lag.  She was not jaundiced.  The neck 
examination revealed diffuse moderate size 
goiter, no bruit over it and the trachea was 
not deviated. She had hand signs of 
thyrotoxicosis (fine tremors and sweating), 
no proximal myopathy.  The cardiovascular, 
chest and abdominal examination were 
normal.  Complete blood count showed; 
White blood cells (WBC) 9.42kU/l, 
hemoglobin (Hb) 10.2 g/dl (Normal 11.5-
16.5), and platelets (PLT) 368k/ul.  
Electrolytes, renal function and blood sugar 
were normal. Total protein 94g/l normal, 
albumin  44g/l, alkaline phosphatase 
418U/L  (Normal 50-136), gamma glutamyl 
transferase (GGT) 924U/L (Normal 5-85), 
Aspartate aminotransferrase (AST) 205U/L 
(Normal 5-50), alanin amino transferase 
(ALT) 234U/L  (Normal 5-65), total bilirubin 
(TBil) was 7 ( Normal).  She had normal 
liver enzymes before the diagnosis of 
thyrotoxicosis.  
Cholesterol 7 mmol/L (Normal 1.2-5.2), and 
triglycerides 1.91 (Normal 0.6-2.3).  The 
patient  was  considered  for  the   statin  
 
(Simvastatin) therapy for her 
hypercholesteremia but this was deferred 
for the risk hepatotoxicity in the presence of 
abnormal liver enzymes.  Thyroid 
stimulating hormone (TSH) 0.011ulU/L 
(Normal 0.27-4.2), Free T4 hormone (FT4) 
94.16 pmol/L (Normal 12-22), Free T3 (FT3) 
39.98pmol/L (Normal 2.8-7). 
Antinuclear antibody (ANA) was 
moderately positive 1:160, double stranded 
DNA antibody was negative, 
Immunoglobulin-G (IgG) 11.8 which was 
normal  Immunoglobulin-M (IgM) 1.19 was 
also normal.   Antimitochondrial antibody 
(AMA2) was negative and smooth muscle 
antibody (SMA) was weakly positive.  
Serology for hepatitis A, B and C viruses 
were negative.  Thyroid peroxidase 
antibody 1309 (Normal 0-34), Thyroid 
Thyroglobulin antiboby (TG) 2263 (Normal 
0-115).  Human Immunodeficiency viruses 
1, 2 (HIV) were negative.  Ultrasound 
abdomen showed fatty liver changes but 
there were no evidence of intra or extra 
hepatic biliary dilatation.  Thyroid 
ultrasound showed diffuse enlargement of 
the gland without focal lesions. Thyroid 
scan demonstrated diffuse increased uptake.  
Liver biopsy showed micro and 
macrovesicular steatosis, some hepatocytes 
showed intracytoplasmic cholestasis and 
mild fibrosis seen in the portal tract.  No 
histological evidence of autoimmune 
hepatitis.  
Because of the clinical and laboratory 
evidence of thyrotoxicosis and failure of 
previous medical treatment she received 
radioactive iodine therapy I131.  Six month 
post I131 treatment the liver enzymes 
improved gradually with the reduction in 
T4 level AST 35U/L, ALT90U/L, Alk 
Pho248U/L. But with the progression to 
hypothyrodism which is expected after I-131 
treatment the liver enzymes showed picture 
of hepatocellular derangements see Table 1.  
The serum lipids were still the same 
metformin 500mg twice daily was started as 
treatment for NAFLD together with 
thyroxin replacement therapy. The liver 
enzymes improved to the lowest level since 
she was diagnosed. 
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Table 1: Fluctuation of the patient’s liver enzymes before and after I131 therapy 
Feature Before I131 6 month after 
I131 
9 month after I131 Last follow up 
TSH 0.011 0.019 64.6 0.85 
T4 94.16 24.19 2.47 29.68 
T3 39.98 5.11 1.73 5.9 
ALP 397 248 263 277 
GGT 708 665 863 660 
AST 205 35 132 90 
ALT 234 90 202 117 
T BIL 7 10 10 3 
 
 
After three years of follow up the liver 
enzymes were still fluctuating but never 
back to normal pravastatin 10 mg daily was 
added and she was closely monitored, she 
had transient improvement of the liver 
enzyme but once again she had poor 
compliance to pravastatin. Currently the 
patient is receiving L thyroxin100 μg/day   
on the latest outpatient follow up the TSH 
.085, T429.68, T3 5.92.  The liver enzymes 
showed hepatocellular derangement 
ALT117, AST90, ALP277 this most likely 
attributed to obesity associated non 




Thyrotoxicosis associated liver enzyme 
abnormality were reported in up to 37% of 
thyrotoxic patients1, 5, 6 The presence of 
cholestasis in association with thyrotoxicosis 
is rarely reported7,8.   This case represents a 
rare association of cholestasis and steatosis 
with thyrotoxicosis.  The abnormality of the 
liver enzymes raises the possibility of 
autoimmune hepatitis in association with 
autoimmune thyroid disorders but this was 
not supported by the finding on the liver 
biopsy and the IgG level, positive ANA is 
not specific and could be related to Grave's 
disease.  Primary biliary cirrhosis (PBC) is 
another autoimmune disease that should be 
considered in an adult female with 
autoimmune thyroid   disorder    presenting  
 
 
with cholestasis, but this was excluded by 
negative (AMA2) antibody, normal (IgM) 
level and absence of PBC features on the 
liver biopsy.  Chronic viral hepatitis ( B or 
C) especially hepatitis C genotype 3 is well 
known to be  associated with steatosis and 
high GGT level9,10  but negative viral 
markers and the liver biopsy findings were 
not supportive for the diagnosis of chronic 
viral hepatitis.  Hepato-toxicity from 
previous Carbimazole treatment is another 
possibility but previously reported cases of 
carbimazole induced cholestasis developed 
during treatment or shortly after and were 
associated with clinical jaundice and 
hyperbilirubinemia 2,3,11 which was not the 
case in our patient, she had normal bilirubin 
and on the other hand she stopped taking 
carbimazole more than one year before she 
had abnormal liver enzymes. I131 was 
reported to cause severe cholestatic 
hepatitis4 but in our patient the liver 
enzymes were abnormal before receiving 
treatment with I131.  In a report similar to our 
patient, Belassoued and colleagues reported 
a case of thyrotoxic hepatitis and steatosis 
with favorable outcome after I131 therapy12.  
In the two reported cases by Hull and 
colleagues the jaundice resolve completely 
after thyroidectomy 8.Toxic liver injury 
related to other drugs or herbal medicine 
was ruled out by history.   The patient had 
normal liver enzymes  before the diagnosis 
of thyrotoxicosis making hyperthyroidism 
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associated cholestasis the  more likely  cause 
of her liver abnormalities, but as compared 
to previously reported cases our patient did 
not had jaundice or hyperbilrubinemia and 
she had  cholestatic rather than 
hepatocelluar derangement of liver 
enzymes.  Another form of thyrotoxicosis 
associated cholestasis was reported in 
association with thyroid storm.8, 13.     The 
patient did not have family history of 
hyperlipidemia but her base line serum 
cholesterol was high.  In spite of low fat diet 
trials and pravastatin she maintained the 
same level of serum cholesterol during the 
follow up but the liver enzymes 
significantly improved after I131. therapy.   
Non alcoholic fatty liver disease (NAFLD) 
and non alcoholic steatohepatitis  (NASH) 
usually present's  with hepatocellular liver 
enzymes  abnormalities  (elevated ALT and 
AST)14 but  NAFLD can sometimes present 
with cholestasis15 but  ALP and GGT are 
poor markers for NASH.14  NAFLD and 
NASH are  likely to be associated with 
hypothyrodism because of weight gain and 
hyperlipidemia this may explain the 
deterioration in the liver enzymes after 
initial improvement  with the evolution 
from hyperthyroidism to hypothyrodism 
after I131 therapy.  The learning lesson from 
this case and from  the reviewed  literature 
that liver enzymes abnormality are 
commonly associated with thyrotoxicosis 
reassessment of the liver enzymes after 
achievement of euothyroid status is 
important to differentiate thyroid associated 
hepatic derangements from other liver 
diseases. 
To conclude, our patient had thyroaoxicosis 
associated cholestasis and steatosis with 
high body mass index, she had significant 
improvement of the liver enzymes   after the 
treatment of thyrotoxicosis.  The pattern of 
hepatic dysfunction changed from 
cholestatic  to hepatocellular picture. 
Thyrotoxicosis associated cholestasis is a 
rare disorder with good response to the 
treatment of thyrotoxicosis.   Its 
pathogenesis and the immunological back 
grounds are not clear.  More data may be 
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